FDA says Distacart's website sells unapproved drugs, some claimed for malaria, asthma, depression and eye conditions.
What happened
FDA reviewed Distacart's website in September 2025 and found products offered for sale in the United States with labeling claims to treat conditions including malaria, asthma, depression, and eye problems. FDA says the products are unapproved new drugs and that no FDA-approved applications are in effect for them.
What FDA found
The website sells drug products without an FDA-approved application, which violates the law.
FD&C Act §§ 301(d), 505(a), 21 U.S.C. §§ 331(d), 355(a)The products are drugs because the website and packaging label them to diagnose, cure, mitigate, treat, or prevent disease or affect body function.
FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1); 21 CFR 201.128The products count as new drugs under the law because they are not generally recognized as safe and effective for their labeled uses.
FD&C Act § 201(p), 21 U.S.C. § 321(p)Some labels claim to treat serious or life-threatening conditions such as malaria, asthma, measles, and depression, which may cause people to delay or stop proven treatment.
Eye drop products are especially risky because medicine put into the eye bypasses some natural defenses.
Being labeled homeopathic does not exempt these products from drug approval, adulteration, or misbranding requirements.
FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1)
What FDA wants
FDA asks the company to notify it in writing within fifteen working days of receipt of the letter about steps taken to correct violations, with explanations and documentation. If correction cannot be completed in that time, the company must state why and when it will be done.
Who should pay attention
- online sellers and marketplaces listing imported homeopathic or Ayurvedic drugs
- consumers using eye drops or products claimed for malaria, asthma, or depression
- brands whose packaging claims appear on third-party retail websites
This is a summary. Read the original letter on fda.gov.